Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BBI503 Monotherapy or with Sorafenib in Advanced Solid Tumors and HCC
NCT02354898Phase 1Completed
- Sponsor
- Sumitomo Pharma
- Start
- Mar 2015
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of amcasertib in solid tumor (advanced stage) and hepatocellular carcinoma (HCC) (2 arms), sponsored by Sumitomo Pharma. Primary endpoints: Maximum Tolerated Dose at 36 days, Number of Participants with Adverse Events at 7 months and 1 more. Started Mar 2015; status: completed.
02
Drugs
amcasertib
03
Conditions
solid tumor (advanced stage)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02354898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02354898.